Introduction
============

It is well known that tumor angiogenesis, which is the formation of new blood vessels in tumors, has a critical role in tumor progression and metastasis ([@b1-etm-0-0-6553]). The heterogeneity of tumor vessels has increasingly been demonstrated. It has been reported that tumor microvascular architecture phenotype (T-MAP), in addition to various bio-characteristics, exhibit heterogeneity and differ from the normal blood vessels ([@b2-etm-0-0-6553],[@b3-etm-0-0-6553]). Thus, using normal vascular endothelial cells (ECs) is inappropriate to investigate tumor angiogenesis or screen candidate anti-cancer drugs that target tumor vessels. It is necessary to harvest tumor endothelial cells (TECs) from tumor tissues. Recently, with the method of magnetic active cell sorting (MACS) that is based on the immunological magnetic beads conjugating various antibodies specifically to endothelial markers such as CD105, CD31 and CD34, many laboratories have made it possible to isolate and purify TECs from tumor mass ([@b4-etm-0-0-6553]--[@b7-etm-0-0-6553]). Of these markers, studies have shown that CD105 is a good marker for tumor angiogenesis in endometrial carcinoma, cervical cancer, breast carcinoma, glioblastoma and esophageal squamous cell carcinoma ([@b8-etm-0-0-6553]--[@b11-etm-0-0-6553]). However, it has been found that CD105 expression levels in tumor vessels vary with cancer development ([@b12-etm-0-0-6553]--[@b14-etm-0-0-6553]).

CD105 is a transmembrane glycoprotein expressed primarily in ECs and tumor cells ([@b15-etm-0-0-6553],[@b16-etm-0-0-6553]). Tumoral CD105 has been defined as a novel independent prognostic marker, whereas the microvessel density labelled by the endothelial marker CD105 (MVD-CD105) negatively correlates with tumor development of human hepatocellular carcinoma (HCC) and renal cell carcinoma ([@b13-etm-0-0-6553],[@b17-etm-0-0-6553]). However, there are conflicting studies as to whether MVD-CD105 is a biological marker for predicting prognosis of cancer. A contrary example is that a higher score of MVD-CD105 appears to correlate with a significantly poorer prognosis in survival rate ([@b14-etm-0-0-6553]). Furthermore, CD105 exhibits a regulatory role in normal human vascular endothelial cells (HUVECs) ([@b18-etm-0-0-6553],[@b19-etm-0-0-6553]).

The aforementioned experimental findings suggest that CD105 expression levels in TECs exist in high and low states, depending on tumor stages. CD31 (PECAM-1), a well-known pan marker for endothelial cells, has also been used for isolation of TECs ([@b20-etm-0-0-6553]). In our laboratory we verified that CD31 is a reliable endothelial marker by phenotypic and functional assays (unpublished data). Thus, in the present study, we applied several approaches to detect CD105 and CD31 expression throughout human HCC tissues with various differentiation status and explored the association between CD105 negative expression in TECs and HCC status using a wide range of samples. CD31^+^ TECs derived from HCC (termed ECDHCC) were isolated and CD105 expression was analyzed in these cells using flow cytometry and confocal microscopy.

Materials and methods
=====================

### Patients and tissue microarray

All procedures of this study involving human materials were performed according to the ethical standards with the Helsinki Declaration and the China Ministry of Health\'s 'Ethical Review of Human Biomedical Research (Tentative, 2007)'. The study was approved by the Research Ethics Board of the Tumor Hospital Affiliated to Nantong University. The written informed consent was obtained as specified in the ethical approval.

We retrospectively collected formalin-fixed paraffin-embedded (FFPE) tissues from 90 HCC patients with the complete clinicopathological data from January 2003 to December 2006. The diagnosis had been done by two pathologists who were blinded to the clinicopathological data at the Tumor Hospital Affiliated to Nantong University. Clinical follow-up data were retrieved from patient records at the Department of Epidemiology in the Tumor Hospital. All underwent hepatic surgical resection without postoperative systemic chemotherapy in the Surgery Department. The main clinical characteristics of the patients are shown in [Table I](#tI-etm-0-0-6553){ref-type="table"}. 78 patients were men and 12 were women. Histological grades were classified to well differentiated (n=38), and poorly differentiated (n=52). Seventy-three were positive for cirrhosis. We prepared 90 pairs (tumor vs. peritumoral tissues) of tissue microarray (TMA) from the aforementioned FFPE tissues. Each patient\'s specimen was represented by a single 1 mm core of tissue. The 90 paired TMAs were used for immunohistochemistry (IHC) staining to detect the expression of CD105 and CD31.

In order to detect endothelial maker expression levels in cells derived from HCC by flow cytometry and confocal microscopic analysis, we collected additional fresh resections, which contained less necrosis tissues, from 15 HCC patients at Tumor Hospital Affiliated to Nantong University from January to December of 2016 with the written informed consent and ethical approval by Research Ethics Committee of Tumor Hospital Affiliated to Nantong University. The clinical characteristics of the patients are shown in [Table I](#tI-etm-0-0-6553){ref-type="table"}. These fresh samples were from 6 male and 9 female patients with 35--75 year of age. Histological grades were classified to well differentiated (n=8), and poorly differentiated (n=7). The diagnosis had been done by two pathologists who were blinded to the clinicopathological data and clinical follow-up data were retrieved from patient records at the Department of Epidemiology in the aforementioned hospital. Single cell suspension was prepared for fluorescent antibody staining. We used these 15 paired samples to check the markers, particularly CD105 expression in tumors vs. peritumoral areas. A positive expression vs. a negative expression in the matched pairs was verified as a convincing result.

### IHC staining and analysis

FFPE slices were dewaxed in xylene and rehydrated in graded alcohol. For blocking of endogenous peroxides, 3% hydrogen peroxide was used for 15 min. Antigen retrieval was routinely performed by immersing the slices in a thermostatic bath containing preheated ethylene diamine tetra acetic acid (EDTA) for 30 min at 98°C and cooling down at room temperature for 20 min. Sections were incubated with monoclonal antibody against a 1:30 dilution of CD105 (mouse-anti-human, clone SN6 h; DAKO, Glostrup, Denmark) and a 1:50 dilution of CD31 (mouse-anti-human, clone JC70A) (both from DAKO, Glostrup, Denmark) overnight at 4°C. Visualization of the antibody complex was achieved with a diaminobenzidine (DAKO) reaction, resulting in brown staining of EC membranes. TMA and slices were counterstained by Meyer\'s hematoxylin.

We used both qualitative and quantitative analysis for evaluation of IHC results. By qualitative analysis, 'negative expression' was indicated by the average number of positive cells from 3 hot spots covering \<5% of the total cells. For quantitative analysis, we used average optical density (AOD) to evaluate the intensity of the IHC reaction in order to compare expression levels between tumor and peritumoral fields of different markers. AOD was performed by Image-Proplus 6.0 software. AOD scores were calculated from the optical density of 5 spots selected randomly on each slice under the microscope (×400).

### Isolation of TECs from HCC

A single cell suspension was firstly prepared from the fresh surgical specimens of the patients with HCC. Briefly, the specimens were minced with scissors and digested by incubation in HANK\'s medium (containing Ca^2+^, Mg^2+^) supplemented with 0.1% collagenase I and collagenase IV (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), and DNase (Cell Culture Grade; Roche Diagnostics, Basel, Switzerland) at 37°C for 45 min. After being washed in medium plus 10% FBS (Sijiqing Co., Ltd., Hangzhou, China), the cells were ready for MACS separation. We used anti-CD31 antibody coupled to magnetic beads and MACS system (Miltenyi Biotech, Bergisch Gladbach, Germany) to separate CD31^+^ TECs from other cells in the cell suspension, according to the instruction manual.

### Cell lines and culture conditions

Normal vascular endothelial cell line (HUVEC) and isolated ECDHCC cells were maintained in endothelial cell growth medium (ECM) supplemented with 5% fetal bovine serum (FBS), 2% VEGF, 100 U/ml penicillin and 100 U/ml streptomycin in 5% CO~2~. All these, including HUVEC cell line were purchased from ScienCell Research Laboratory (Yuhenfeng Company, Beijing, China).

### Flow cytometric analysis

The first step was the preparation of a single cell suspension. The cultured HUVEC cells were detached from plates with a nonenzymatic cell dissociation solution (Sigma-Aldrich; Merck KGaA) and washed in PBS containing 0.5% BSA. The fresh surgical specimens were enzymatically dissociated into a single cell suspension. Cells were then incubated for 15 min at 4°C with the appropriate antibodies or with a control in PBS containing 0.5% bovine serum albumin (BSA). Cells were analyzed on Becton Dickinson FACS Aril II. We used primary murine monoclonal antibodies against human CD105 conjugated to allophycocyanin (APC) (1:30 dilutions) and human CD31 conjugated to phycoerythrin (PE) (1:100 dilutions). Unstained cells were used to distinguish between fluorescent positive and fluorescent negative populations. 7-AAD was added for 10 min prior to FACS analysis, which allowed for the discrimination of dead vs. live cells. All antibodies were purchased from Becton Dickinson (Franklin Lakes, NJ, USA).

### Confocal microscopy analysis

Immunofluorescent double staining analysis was performed on ECDHCC and HUVECs which were seeded on sterile slice cover slips in six well plates overnight. Following several washes with PBS, cells were fixed with 4% paraformaldehyde for 30 min at room temperature and permeabilized with 0.1% Triton X-100 in PBS for 5 min. The cells were overlaid with 5% BSA for 30 min, rinsed with PBS and incubated with a mixture of rabbit-anti-human CD105 (1:20 dilutions; Abcam, Cambridge, UK) and mouse-anti-human CD31 (1:40 dilutions; DAKO) or a mixture of rabbit-anti-human CD105 (1:20 dilutions) and mouse-anti-human VEGFR-2 (1:200 dilutions) (both from Abcam) overnight at 4°C. Cells were washed three times with PBS and then incubated with Alex-488-conjugated donkey-anti-rabbit IgG and Dylight-649-conjugated donkey-anti-mouse IgG (1:200 dilutions, Jackson ImmunoResearch, West Grove, PA, USA) secondary antibodies. The slices were incubated at 37°C for 45 min, and nuclear staining was performed with DAPI. Coverslips were mounted with fluorescent mounting medium onto glass slides, and examined with confocal microscopy (Leica TCS SP5II; Leica Microsystems, Wetzlar, Germany). Images were collected from at least three independent experiments and processed for presentation in figures using Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA, USA).

### Statistical analysis

The stata17 software package was used for all statistical analyses. Comparisons between paired samples were determined by Wilcoxon signed-rank test. For the quantitative analysis of endothelial expression, one way ANOVA with post hoc test (Student-Newman-Keuls) was used for multiple comparisons of the merged areas covering CD105 with CD31 or VEGFR2. For clinical data analysis, a Chi-square test was used. A P-value of \<0.05 was considered statistically significant.

Results
=======

### Sections of FFPE tissues derived from patients with HCC lacked endothelial CD105 expression

As presented in [Fig. 1](#f1-etm-0-0-6553){ref-type="fig"} by IHC detection, CD31 was universally present in vessels of all tumor and corresponding peritumoral tissues ([Fig. 1A](#f1-etm-0-0-6553){ref-type="fig"}). Similarly, CD105 presented in all peritumoral tissues. However, CD105 in tumor tissues was differentially expressed: Of 15 patients with HCC, 9 tumor FFPE tissues presented CD105 abundantly in the vessels and in some tumor cells ([Fig. 1B](#f1-etm-0-0-6553){ref-type="fig"}); whereas 6 tumor FFPE tissues appeared to exhibit weak or negative CD105 expression ([Fig. 1C](#f1-etm-0-0-6553){ref-type="fig"}). Quantitative analysis revealed the differences of intensity between CD31 and CD105 expression, as well as between tumor and peritumoral tissues. Notably, the intensity of CD105 in those 6 tumor FFPE tissues with little or no CD105 expression (AOD=5±2) was significantly decreased when compared with corresponding peritumoral tissues (AOD=55±4), P\<0.01 ([Fig. 1D](#f1-etm-0-0-6553){ref-type="fig"}).

Furthermore, we qualitatively scored CD31 and CD105 expression in tumor vessels by TMA and found that among 90 patients with HCC, CD31 was expressed in tumor vessels of all TMA specimens including tumor and peritumoral areas ([Fig. 2A-D](#f2-etm-0-0-6553){ref-type="fig"} and [Table II](#tII-etm-0-0-6553){ref-type="table"}), whereas in 39 out of 90 cases (43.3%) CD105 expression was absent in tumors in contrast to corresponding peritumoral tissues in which CD105 was present ([Fig. 2E-L](#f2-etm-0-0-6553){ref-type="fig"} and [Table II](#tII-etm-0-0-6553){ref-type="table"}). In addition, the overall intensity of the CD105 signal in tumors (AOD=19.2±4.6) was markedly low, compared with CD31 (AOD=90±4.6) as well as with the intensity of CD105 in peritumor tissues (AOD=31.3±5.6) (P\<0.05) ([Fig. 2M](#f2-etm-0-0-6553){ref-type="fig"}). To investigate the clinical implication of CD105 expression variation, we retrospectively analyzed the clinicopathological data and found that of 39 CD105 negative cases, only 10 cases (25.6%) were in the well-differentiated group, and the remaining 29 cases (74.4%) were in the poor-differentiated group ([Table III](#tIII-etm-0-0-6553){ref-type="table"}). Furthermore, the overall survival in the remaining 29 patients was significantly reduced (data not shown). In brief, the present results revealed that low or negative expression of CD105 in tumor vessels may indicate the deterioration of disease.

### Variation in CD31 and CD105 expression levels at the cellular level, detected via flow cytometry and confocal microscopy analysis

In order to effectively conduct these assays to detect endothelial markers at the cellular level, a TEC single cell suspension was required. We respectively isolated TECs from 11 fresh resections from patients with HCC that were selected from the 15 aforementioned cases. Representative profiles from the flow cytometry analysis revealed that the CD31 expression level was 92.2, 15.2, and 9.7% respectively in HUVECs, well- and poor-differentiated groups ([Fig. 3A](#f3-etm-0-0-6553){ref-type="fig"}). CD105 expression was 43.6 and 4.9% in HUVECs and the well-differentiated group, respectively. A representative sample of patients with poor-differentiated HCC demonstrated undetectable levels of CD105 ([Fig. 3B](#f3-etm-0-0-6553){ref-type="fig"}). CD31^+^CD105^+^ double positive cells in HCC tissues decreased compared with in HUVECs (as a positive control) ([Fig. 3C](#f3-etm-0-0-6553){ref-type="fig"}). The result indicated that the more advanced the stage of HCC, the lower the expression level of CD105.

Using 'double staining' in cells for confocal microscopy analysis makes it possible to detect co-localization of two endothelial makers in a cell. We performed 'double staining' in TEC (ECDHCC) and HUVECs (control) with 3 endothelial markers CD31, CD105 and VEGFR-2. As shown in [Fig. 4](#f4-etm-0-0-6553){ref-type="fig"}, the representative images revealed that CD31 or VEGFR-2 were expressed abundantly in ECDHCC cells from all tested samples regardless of the degree of differentiation, in addition to HUVECs ([Fig. 4A-F](#f4-etm-0-0-6553){ref-type="fig"} in the left 2 panels). However, CD105 positive expression presented in the well-differentiated cases (n=6/11) only ([Fig. 4B and E](#f4-etm-0-0-6553){ref-type="fig"} left panels), and little or no CD105 was expressed in the poor-differentiated cases (n=5/11) ([Fig. 4C and F](#f4-etm-0-0-6553){ref-type="fig"} left panels). On investigation of co-expression of CD105 with other endothelial markers, it was observed that an increased level of co-expression of CD105 with CD31 or VEGFR-2 appeared in HUVECs with 83.3±5.2 and 70.7±3.9% of cover area ([Fig. 4A-D](#f4-etm-0-0-6553){ref-type="fig"}, right panels and 4G). In the well-differentiated group, the merged areas of CD105 co-expressed with CD31 or VEGFR-2 were 56.8±2.6 and 55.3±4.8% ([Fig. 4B-E](#f4-etm-0-0-6553){ref-type="fig"}, right panels and 4G). Whereas there was little or no merged area in the poor-differentiated group ([Fig. 4C-F](#f4-etm-0-0-6553){ref-type="fig"}, right panels). The difference of the merged areas of CD105 with CD31 or VEGFR-2 between the well- and poor-differentiated group was significant (P\<0.01) ([Fig. 4G](#f4-etm-0-0-6553){ref-type="fig"}).

Discussion
==========

Antiangiogenic therapies aim to inhibit tumor angiogenesis by targeting the tumor blood vessels and lead to a 'starvation effect' on tumors and are extensively applied in clinical solid cancer treatment ([@b21-etm-0-0-6553],[@b22-etm-0-0-6553]). However, it has recently been noted that the efficiency of current antiangiogenic cancer therapy is limited and the treatment outcomes are different. This may potentially be due to the complex process of tumor angiogenesis, that leads to heterogeneity of tumor microvascular structures, including T-MAP ([@b2-etm-0-0-6553]), and multiple cell sources of recruitment for tumor angiogenesis, including cancer stem-like cells ([@b23-etm-0-0-6553],[@b24-etm-0-0-6553]), bone marrow-derived endothelial and hematopoietic precursor cells ([@b25-etm-0-0-6553]). Current drugs targeting tumor angiogenesis have been developed based on studies using normal ECs. Thus, it is necessary to isolate endothelial cells from tumor tissue for further understanding and improved treatment options and specificity.

Recently, several laboratories have isolated TECs using a variety of methods, however MACS is a far more specific method. Typically, endothelial markers including CD31, CD34 and CD105 are used for making antibodies that are bound with the magnetic beads, so that the cells expressing these markers can be positively selected. However, it is a controversial issue as to which type of endothelial molecule, as a stable marker, can be used for isolation of TECs. CD31 is known as a pan endothelial marker ([@b26-etm-0-0-6553],[@b27-etm-0-0-6553]). In our previous study, we phenotypically and functionally identified CD31^+^ TECs from human HCC mass (unpublished data). CD34 has also been used for isolation of TEC cells ([@b28-etm-0-0-6553]), however is primarily expressed in hematopoietic stem/progenitor cells ([@b29-etm-0-0-6553]). CD105 not only serves as an endothelial marker ([@b11-etm-0-0-6553],[@b30-etm-0-0-6553]) but is also expressed in tumor cells and thus may act as a prognosis marker for cancer ([@b13-etm-0-0-6553],[@b31-etm-0-0-6553]). These results indicate that the cells isolated using CD105-MACS contain both endothelial CD105^+^ and tumoral CD105^+^ cells.

The present study demonstrated that all 90 HCC-TMA cases exhibited CD31 expression in tumor tissue spots, whereas of these samples 39 HCC-TMA cases exhibited little or no CD105 expression in tumors, however this was not the case in peritumoral tissue spots. Of the 39 cases with negative CD105 expression, 29 cases (74.4%) were poor-differentiated HCC. Interestingly, we found that the more advanced the stage of HCC, the lower the expression level of CD105. These findings were further verified by FACS analysis of CD31 and CD105 expression levels in a single cell digested from 11 HCC tissues, and by confocal analysis of TECs isolated from the same 11 HCC tissues. We found that HCC with poor differentiation did not express CD105. Similar to our data, it was demonstrated that CD105 has a lower expression in HCC compared with tumor free tissues, by MVD-CD105 ([@b13-etm-0-0-6553]). CD105 was also demonstrated to be completely negative in 28 cases of 86 HCC sections examined ([@b17-etm-0-0-6553]). Conversely, endothelial CD105 has a high expression in a wide range of cancers, including colon, breast, brain, lung, prostate and cervical ([@b4-etm-0-0-6553]).

On comparison of CD105 with CD31 in tumor vessels of HCC, our study demonstrated that there might be a limitation to use CD105 as an endothelial marker for isolation of TECs, particularly in poor-differentiated HCC cases, due to lacking CD105 expression. In addition, there might be a potential risk of a contamination with CD105^+^ tumor cells. We believe that CD31, and not CD105 is a reliable endothelial marker for isolation of TECs. Further research is required in order to clarify the potential mechanisms.
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![Endothelial marker expression in vessels of HCC tissues. Immunohistochemistry staining of CD31 and CD105 was carried out in 15 fresh HCC tissues. (A) Representative image of CD31 expression in tumor and peritumoral tissues. Representative images of (B) CD105 positive (slice1-CD105) or (C) CD105 negative (slice2-CD105) expression in tumor tissues, respectively. (D) Average optical density (AOD) of CD31 (n=15), CD105 (positive, n=9) and CD105 (negative, n=6). Magnification ×100. T, tumor, P, peritumoral tissues. \*\*P\<0.01.](etm-16-04-2881-g00){#f1-etm-0-0-6553}

![Tumor vessels with or without CD105 expression on TMA of HCC. (A-D) Representative images of CD31 expression in the T and P tissues (n=90 pairs). (E-H) Representative images of CD105-positive expression in T and P tissues (n=51 pairs). (I-L) Representative images of CD105-negative expression in tumor (I and K) and positive expression of CD105 in peritumoral (J and L) tissues (n=39 pairs). Magnification ×40 for A, B, E, F, I, J images, ×100 for C, D, G, H, K, L images of TMA. (M) Total average optical density of CD31 and CD105 expression in tumor and peritumoral tissues (n=90 pairs). \*P\<0.05. T, tumor; P, peritumoral.](etm-16-04-2881-g01){#f2-etm-0-0-6553}

![Flow cytometric analysis of expression levels of CD105 and CD31 in different HCC cases. Representative images of (A) CD31 and (B) CD105 staining in HUVECs (control), single cells from well- and poor-differentiated HCC, respectively. (C) Double staining of HUVECs, single cells from well- and poor-differentiated HCC with anti-CD31 and anti-CD105 antibodies.](etm-16-04-2881-g02){#f3-etm-0-0-6553}

![Confocal analysis of co-expression of CD105 with other endothelial markers in ECDHCC cells. Double staining of HUVECs (control) (A), ECDHCC1 (well-differentiated HCC, n=6) (B) and ECDHCC2 (poor-differentiated HCC, n=5) (C) with anti-CD105 and anti-CD31 antibodies. Double staining of HUVECs (D), ECDHCC1 (E) and ECDHCC2 (F) with anti-CD105 and anti-VEGFR-2 antibodies. (G) Quantitative analysis of the merged area covering CD105 with CD31 or VEGFR2. Anti-CD105, -CD31 and -VEGFR-2 antibodies were respectively labelled with Alex-488 (green) and Dylight-649 (red). Magnification ×400. \*P\<0.05, \*\*P\<0.01.](etm-16-04-2881-g03){#f4-etm-0-0-6553}

###### 

Clinical characteristics of 90 paired FFPE and 15 fresh tissues from patients with HCC.

  Parameter               FFPE tissues n=90 (%)   Fresh tissues n=15 (%)
  ----------------------- ----------------------- ------------------------
  Age, years                                      
    ≤45                   33 (36.7)               5 (33.3)
    \>45                  57 (63.3)               10 (66.7)
  Sex                                             
    Male                  78 (86.7)               6 (40.0)
    Female                12 (13.3)               9 (60.0)
  Tumor differentiation                           
    Well                  38 (42.2)               8 (53.3)
    Poor                  52 (57.8)               7 (46.7)
  Tumor size, cm                                  
    ≤5                    51 (56.7)               8 (53.3)
    \>5                   39 (43.3)               7 (46.7)
  Capsular integrity                              
    Positive              57 (63.3)               9 (60.0)
    Negative              33 (36.7)               6 (40.0)
  Metastasis                                      
    Positive              14 (15.6)               3 (20.0)
    Negative              76 (84.4)               12 (80.0)
  Vascular invasion                               
    Positive              67 (74.4)               7 (46.7)
    Negative              23 (25.6)               8 (53.3)
  Liver cirrhosis                                 
    Positive              73 (81.1)               11 (73.3)
    Negative              17 (18.9)               4 (26.7)
  AFP, ng/ml                                      
    ≤50                   34 (37.8)               6 (40.0)
    \>50                  56 (62.2)               9 (60.0)

FFPE, formalin-fixed paraffin-embedded; HCC, hepatocellular carcinoma; AFP, α fetoprotein. n, the number of the case.

###### 

Overall analysis of HCC blood vessels with or without CD31 and CD105 expression by TMA with IHC staining.

               Expression (%)               
  ------- ---- ---------------- ----------- --------
  CD105   90   39 (43.3)        51 (56.7)   \<0.01
  CD31    90   0 (0)            90 (100)    

HCC, hepatocellular carcinoma; IHC, immunohistochemistry; TMA, tissue microarray; n, the number of the case.

###### 

Clinical implication of the 39 cases with negative expression of CD105.

  Cases                     Well (%)       Poor (%)
  ------------------------- -------------- --------------
  Total no. of cases        10/90 (11.1)   29/90 (32.2)
  No. of CD105^neg^ cases   10/39 (25.6)   29/39 (74.4)

Well, well-differentiation of HCC, in which the characteristics of cancer cells were that the ratio of nucleus/cytoplasm was slightly increased, and nuclear atypia was minimal; Poor, poor-differentiation of HCC, in which the characteristics of cancer cells were that the ratio of nucleus/cytoplasm was obviously increased, and the nuclei was hyperchromasia and nuclear borders were irregular. CD105neg, negative expression of CD105 on TMA slices. CD105^neg^, negative expression of CD105 on tissue microarray slices; HCC, hepatocellular carcinoma.
